Publications by authors named "A Vanden Abbeele"
Accurate lymph node size estimation is critical for staging cancer patients, initial therapeutic management, and assessing response to therapy. Current standard practice for quantifying lymph node size is based on a variety of criteria that use uni-directional or bi-directional measurements. Segmentation in 3D can provide more accurate evaluations of the lymph node size.
View Article and Find Full Text PDFArticle Synopsis
- - The study focused on gastrointestinal stromal tumors (GISTs), which often have mutations in the KIT or PDGFRA proteins, making them targets for the drug imatinib mesylate.
- - Analysis of tumors from 127 patients revealed that 88.2% had KIT mutations (mostly in exons 9 and 11), with those having exon 11 mutations showing an 83.5% response rate to imatinib, while those with exon 9 mutations or no detectable mutations had lower response rates.
- - The findings highlight that the presence and type of mutations in KIT or PDGFRA are significant indicators of how well patients with GISTs might respond to imatinib treatment.
In a prospective clinical trial, [F]fluoro-5α-dihydrotestosterone ([F]FDHT), the radiolabeled analog of the androgen dihydrotestosterone, was used as a PET/CT imaging agent for in vivo assessment of metastatic androgen receptor-positive breast cancer in postmenopausal women. To our knowledge, this article presents the first report of PET/CT image-based radiation dosimetry of [F]FDHT in women. [F]FDHT PET/CT imaging was performed on a cohort of 11 women at baseline before the start of therapy and at 2 additional time points during selective androgen receptor modulator (SARM) therapy for androgen receptor-positive breast cancer.
View Article and Find Full Text PDFResponse assessment in the context of immunomodulatory treatments represents a major challenge for the medical imaging community and requires a multidisciplinary approach with involvement of oncologists, radiologists, and nuclear medicine specialists. There is evolving evidence that [F]FDG PET/CT is a useful diagnostic modality for this purpose. The clinical indications for, and the principal aspects of its standardization in this context have been detailed in the recently published "Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.
View Article and Find Full Text PDF